Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Phenyl group

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    57 result(s) found for: Phenyl group. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-004449-40 Sponsor Protocol Number: BAY 59-7939/11898 Start Date*: 2007-02-02
    Sponsor Name:Bayer HealthCare AG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination with Aspirin Alone or with...
    Medical condition: Acute Coronary Syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.1 10051592 Acute coronary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) HU (Completed) BE (Completed) NL (Completed) DK (Completed) CZ (Completed) SE (Completed) SK (Completed) GB (Completed) BG (Completed) FI (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-004844-23 Sponsor Protocol Number: 20101299 Start Date*: 2012-06-12
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Study 299)
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004845-42 Sponsor Protocol Number: 20110165 Start Date*: 2012-05-30
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Study 165)
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    16.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004430-15 Sponsor Protocol Number: GS-US-356-0101 Start Date*: 2014-10-07
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Double-Blind, Randomized, Placebo Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects with Implantable Cardioverter-Def...
    Medical condition: Subjects with an ICD or CRT-D implanted for primary or secondary prevention
    Disease: Version SOC Term Classification Code Term Level
    17.1 10007541 - Cardiac disorders 10047281 Ventricular arrhythmia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) DK (Completed) CZ (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-000743-33 Sponsor Protocol Number: SPD602-204 Start Date*: 2014-01-16
    Sponsor Name:Shire Development LLC and International Affiliates
    Full Title: A 48-week, Open-label, 2-arm, Parallel-group, Randomized Exploratory Study to Assess Liver Iron Concentration Measured by FerriScan® (R2) Magnetic Resonance Imaging in β-thalassemia Subjects Admin...
    Medical condition: Patients 18 years of age and older with transfusional iron overload due to β-thalassemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10065974 Chronic iron overload LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006100-11 Sponsor Protocol Number: 203818-503 Start Date*: 2007-06-25
    Sponsor Name:Allergan Ltd
    Full Title: A multicenter, multiple dose, double-blind, randomized, placebo-controlled, parallel group study of the safety and efficacy of AGN 203818 in female patients with fibromyalgia syndrome.
    Medical condition: Fibromyalgia syndrome in female patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10016631 Fibromyalgia syndrome LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000612-54 Sponsor Protocol Number: 0782-003 Start Date*: 2004-09-11
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Multicenter, Randomized, Parallel-Group, Active-Controlled Double-Blind Study Conducted Under In-House Blinding Conditions to Determine the Incidence of Gastroduodenal Ulcers in Patients With Ost...
    Medical condition: Osteoarthritis (OA) ICD: M19.9 MedDRA: 10031161 Rheumatoid Arthritis (RA) ICD: M06.9 MedDRA: 10039037
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004595-13 Sponsor Protocol Number: BAY59-7939/11630 Start Date*: 2009-03-09
    Sponsor Name:Bayer HealthCare AG
    Full Title: A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-inferiority Study Comparing the Efficacy and Safety of Once Daily Oral Rivaroxaban (BAY 59-7939...
    Medical condition: Prevention of Stroke and Non-CNS Systemic Embolism in Non-Valvular Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003658 Atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) NL (Completed) DK (Completed) BE (Completed) HU (Completed) SE (Completed) LT (Completed) GB (Completed) CZ (Completed) FR (Completed) BG (Completed) GR (Completed) AT (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-001580-11 Sponsor Protocol Number: LuAA21004_305 Start Date*: 2009-04-09
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025463 Major depressive disorder, single episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed) NL (Completed) LV (Completed) LT (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-006088-23 Sponsor Protocol Number: MEK116513 Start Date*: 2012-06-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III, randomised, open-label study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to the BRAF inhibitor vemurafenib in subjects with unresectab...
    Medical condition: Metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) BE (Completed) AT (Completed) NO (Completed) IE (Completed) CZ (Completed) ES (Completed) NL (Completed) HU (Completed) FI (Completed) IT (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2022-000073-12 Sponsor Protocol Number: PTC596-ONC-008-LMS Start Date*: 2022-06-22
    Sponsor Name:PTC Therapeutics, Inc.
    Full Title: A PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UNESBULIN IN UNRESECTABLE OR METASTATIC, RELAPSED OR REFRACTORY LEIOMYOSARCOMA
    Medical condition: Leiomyosarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10024190 Leiomyosarcomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) IT (Completed) PL (Prematurely Ended) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004630-14 Sponsor Protocol Number: BFS-AS-40035 Start Date*: 2014-01-23
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A 12 Week, Randomized, Open-Label, Parallel Group Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) Spiromax(160/4.5 and 320/9 mcg) as Compared to SYMBICORT® TURBOHA...
    Medical condition: Persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004577-12 Sponsor Protocol Number: BRF116613 Start Date*: 2015-03-23
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: Phase II biomarker study evaluating the upfront combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib versus the combination after eight weeks of monotherapy with dabrafenib or tra...
    Medical condition: patients with metastatic and unresectable stage III or IV melanoma harbouring an activating BRAF mutation
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-004614-14 Sponsor Protocol Number: BAY 59-7939/12839 Start Date*: 2007-12-05
    Sponsor Name:Bayer HealthCare AG
    Full Title: MAGELLaN - Multicenter, rAndomized, parallel Group Efficacy and safety study for the prevention of venous thromboembolism in hospitalized medically iLL patients comparing rivaroxabAN with enoxaparin
    Medical condition: Prevention of venous thromboembolism in patients who have been hospitalized for a medical illness
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012108 Deep venous thrombosis prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) FR (Completed) DK (Completed) LT (Completed) GB (Completed) BE (Completed) AT (Completed) NL (Completed) ES (Completed) GR (Completed) PT (Completed) SI (Completed) SK (Completed) CZ (Completed) IT (Completed) PL (Completed) LV (Completed) FI (Completed) HU (Completed) EE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-005949-38 Sponsor Protocol Number: M10-265 Start Date*: 2008-09-29
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone as First-line Treatment in Subjects With Locally Recurrent or Metastat...
    Medical condition: Metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended) CZ (Completed) BE (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002501-22 Sponsor Protocol Number: PHP-303-A201 Start Date*: 2020-05-04
    Sponsor Name:pH Pharma Inc.
    Full Title: A Multi-Center, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Tolerability of the Neutrophil Elastase Inhibitor PHP-303 in Adults with Alpha-1 Antitrypsin Defic...
    Medical condition: Alpha-1 Antitrypsin Deficiency
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-019872-65 Sponsor Protocol Number: MK-0663-108 Start Date*: Information not available in EudraCT
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patie...
    Medical condition: Ankylosing Spondylitis (AS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) FI (Completed) BE (Completed) AT (Completed) GB (Completed) EE (Completed) SK (Completed) CZ (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002472-99 Sponsor Protocol Number: EVT302/3009 Start Date*: 2008-08-12
    Sponsor Name:Evotec Neurosciences GmbH
    Full Title: A phase II multicenter, randomised, double-blind, parallel group, placebo-controlled, study to evaluate the effectiveness of EVT 302 in smoking cessation, effect on its own and in combination with ...
    Medical condition: Male or female subjects who are chronic smokers, but motivated to quit smoking will be recruited.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002315-17 Sponsor Protocol Number: MGL-3196-06 Start Date*: 2017-01-12
    Sponsor Name:Madrigal Pharmaceuticals, Inc.
    Full Title: A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia
    Medical condition: Heterozygous Familial Hypercholesterolemia (HeFH)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-000190-28 Sponsor Protocol Number: IMD-10412002-1 Start Date*: 2007-03-22
    Sponsor Name:Institute of Medicinal Molecular Design Inc
    Full Title: A Single Centre, Double-blind, Randomised Study To Investigate a Single Oral Dose of IMD-1041 in A Nasal Allergen Challenge (NAC) Model
    Medical condition: It is intended to investigate the potential therapeutic benefit of IKKβ inhibition in man by oral dosing of IMD-1041 in a Nasal Alllergen Challenge.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10053467 Antiinflammatory therapy PT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 13 06:48:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA